In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on Applied DNA Sciences (APDN), with a price target of $3. The company’s shares opened today at $1.13, close to its 52-week low of $0.98.
Vendetti observed:
“Today, before the Market open, APDN reported preliminary F4Q18 (Sept) revenue and GAAP loss per share figures that missed our estimates.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 5.4% and a 47.5% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
Currently, the analyst consensus on Applied DNA Sciences is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.80 and a one-year low of $0.98. Currently, Applied DNA Sciences has an average volume of 148.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied DNA Sciences, Inc. engages in the security solutions. It provides biotechnology-driven solutions to help protect products, brands, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
